Media Summary: Dr Punie discusses the patient-reported outcomes (PROs) from the Phase 3 ASCENT-03 study, comparing Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier ... Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, takes us through a study which evaluated the efficacy ...
Sacituzumab Govitecan Improves Quality Of - Detailed Analysis & Overview
Dr Punie discusses the patient-reported outcomes (PROs) from the Phase 3 ASCENT-03 study, comparing Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier ... Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, takes us through a study which evaluated the efficacy ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III ... Hope Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides an overview of ...
Kevin Kalinsky, MD, MS, Emory University, Atlanta, GA, progression-free survival after next line of treatment (PFS2) analyses from ... Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute evaluating the safety and effectiveness of ... Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world Lisa Carey, MD, ScM, FASCO, from the University of North Carolina, Chapel Hill, NC, outlines the pivotal Phase III trial ASCENT ... Patients reported lower symptomatic impact of fatigue, pain, and dyspnea. Prof Hope Rugo speaks to ecancer on the overall survival results from the phase III TROPiCS-02 study of
Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a biomarker analysis of the Phase III ...
